Lisata Therapeutics, Inc. (8NE.F)
| Previous close | 2.4800 |
| Open | 2.4800 |
| Bid | 2.5800 x N/A |
| Ask | 2.8200 x N/A |
| Day's range | 2.4800 - 2.4800 |
| 52-week range | 1.7400 - 4.0400 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 21.252M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4000 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireLisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N. J., May 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious
- GlobeNewswire
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
BASKING RIDGE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in May: Pharma Partnering U.S. Summit (May 14-15, 2024) Format: In-personLocation: San Diego, California Lisata Representative: Tariq Imam, VP of Business Devel
- GlobeNewswire
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for three months ended March 31, 2024, on Thursday, May 9, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing t
